Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ Continues To Buy Pipeline With $100M Rigel Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.

You may also be interested in...



Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal

Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.

Fostamatinib Skates Through OSKIRA-1 With Mixed Results

AstraZeneca/Rigel’s oral SYK inhibitor fostamatinib met a key primary endpoint in the first of three rheumatoid arthritis Phase III studies, but missed another. Investors and analysts are underwhelmed with the efficacy results, although President and COO Raul Rodriguez advises holding on for the other Phase III trials before passing judgment.

Fostamatinib Skates Through OSKIRA-1 With Mixed Results

AstraZeneca/Rigel’s oral SYK inhibitor fostamatinib met a key primary endpoint in the first of three rheumatoid arthritis Phase III studies, but missed the other. Investors and analysts are underwhelmed with the efficacy results, although President and COO Raul Rodriguez advises holding on for the other Phase III trials before passing judgment.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel